



PATENT
Attorney Docket 057971-5006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Margherita T. Cantorna <i>et al.</i>)	Confirmation No. 4418
)	
Application No. 10/674,395)	Group Art Unit: 1623
)	
Filed: October 1, 2003)	Examiner: Eric Olson
)	
For: PPAR-γ Ligands in the Treatment of)	
Asthma and Allergies)	

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97(c)

Pursuant to 37 C.F.R. 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed to the best of the undersigned's knowledge before the mailing date of a Final Office Action or a Notice of Allowance for the above-referenced application. Under the provisions of 37 C.F.R. 1.97(c), the Commissioner is hereby authorized to charge the fee of \$180.00 as specified by 1.17(p) to Deposit Account 50-0310.

Copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form. This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed documents are material or constitute prior art. If the Examiner applies any of the documents as prior art against any claim in the application, and Applicants determine that the cited documents do not constitute prior art under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should the documents be applied against the claims of the present application.


Except for issue fees payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this

02/13/2007 SZEWDIE1 00000156 500310 10674395
02 FC:1806 180.00 DA

application including fees due under 37 C.F.R. 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **Constructive Petition for Extension of Time** in accordance with 37 C.F.R. 1.136(a)(3).

Dated: **February 12, 2007**
Morgan, Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Ave., N.W.
Washington, D.C. 20004
Tele: 202-739-3000
Fax: 202-739-3001

Respectfully submitted,
Morgan, Lewis & Bockius LLP


Elizabeth C. Weimar
Registration No. 44,478



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO Form 1449				Atty. Docket 057971-5006		Application No. 10/674,395			
				Applicants: Margherita T. Cantorna <i>et al.</i>				Page 1 of 1	
				Filing Date: October 1, 2003		Group Art Unit: 1623			
U.S. PATENT DOCUMENTS									
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date		
FOREIGN PATENT DOCUMENTS									
		Document No.	Date	Country	Class	Sub-Class	Translation		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)									
	aa	August <i>et al.</i> , "Nutrients, Nuclear Receptors, Inflammation, Immunity Lipids, PPAR, and Allergic Asthma," Symposium: Nutrients, Nuclear Receptors, Inflammation, and Immunity, American Society for Nutrition, pp. 695-699 (April 3, 2005 at Experimental Biology 2005, San Diego, California)							
	ab	Walter <i>et al.</i> , "Critical Role for IL-13 in the Development of Allergen-Induced Airway Hyperreactivity," J. Immunol. (2001) 167:4668-4675							
	ac	Webb <i>et al.</i> , "Integrated Signals Between IL-13, IL-4, and IL-5 Regulate Airways Hyperreactivity," J. Immunol. (2000) 165:108-113							
	ad	Wills-Karp <i>et al.</i> , "Interleukin-13: Central Mediator of Allergic Asthma," Science (1998) 282:2258-2261							
	ae	Zhu <i>et al.</i> , "Pulmonary Expression of Interleukin-13 Causes Inflammation, Mucus Hypersecretion, Subepithelial Fibrosis, Physiologic Abnormalities, and Eotaxin Production," J. of Clinical Investigation (1999) 103(6):779-788							
Examiner		Date Considered							
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									